DRESS syndromeMANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

416 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp65

Immediate recognition and stabilization

›DRESS phenotype recognition

›Fever

›Morbilliform eruption evolving to oedematous confluent erythema

›Facial oedema

›Lymphadenopathy at two or more sites

›Eosinophilia or atypical lymphocytosis

›Hepatitis, nephritis, pneumonitis, or myocarditis concern

›Culprit drug identification and cessation

›Review all medications started in the preceding 2 to 8 weeks

›Long latency is the defining feature distinguishing DRESS from other drug eruptions

›Culprit is frequently missed because the latency exceeds the typical drug-reaction recall window

›Immediate and complete cessation of the suspected culprit and cross-reactive agents

›Class I recommendation based on expert consensus

›Never rechallenge with the culprit drug

›Airway and hemodynamic assessment

›Facial and pharyngeal oedema — airway compromise uncommon but assess if present

›Hypotension or shock physiology

›Consider fulminant myocarditis as a cause, not only sepsis or capillary leak

›Continuous cardiac monitoring for myocarditis concern

›Initial stabilization targets

›IV access

›Continuous pulse oximetry

›Cardiac telemetry

›Temperature management

Iatrogenic harms of routine ED interventions

›Intubation and sedation

›Airway compromise from DRESS itself is uncommon — intubate for standard indications only

›Hepatically metabolized sedatives and paralytics require dose reduction or avoidance if hepatitis is present

›Reduced hepatic clearance prolongs sedation and delays neurologic reassessment

›Fluid loading

›Aggressive crystalloid bolusing risks precipitating pulmonary oedema if undiagnosed myocarditis is present

›Assess for myocarditis before large-volume resuscitation in DRESS with hypotension

›Interstitial nephritis may impair free water and sodium handling — reassess volume status frequently

›Oxygen

›Supplemental oxygen for pneumonitis-associated hypoxemia

›Hyperoxia not indicated once saturation targets are met

›Vasopressors

›Pure vasoconstrictors increase afterload on a myocarditis-weakened ventricle

›Inotropic support preferred over vasoconstriction alone in confirmed myocarditis-driven shock

›Cardiology or critical care input before vasopressor selection in suspected myocarditis

›Mechanical circulatory support

›Intra-aortic balloon pump or extracorporeal membrane oxygenation as a bridge in fulminant DRESS myocarditis with cardiogenic shock

›Early cardiology and critical care consultation for fulminant presentations

›Anticoagulation and fibrinolysis

›Check coagulation studies before anticoagulating — severe hepatitis can cause synthetic coagulopathy and bleeding risk

›Fibrinolysis caution if hepatic synthetic dysfunction is present — elevated bleeding risk

›Analgesia and antipyretics

›NSAIDs relatively contraindicated with hepatic or renal involvement

›Ibuprofen 400 mg PO q6h PRN — avoid if transaminases are elevated or creatinine is rising

›Acetaminophen dosing

›Acetaminophen 650 to 1000 mg PO q6h PRN

›Maximum 3 g per day if hepatitis is present, reduced from the standard 4 g maximum daily dose

›Avoid supratherapeutic dosing — hepatitis reduces reserve for additional hepatotoxic insult

›Opioids hepatically metabolized (tramadol, codeine) may need dose reduction or avoidance with hepatic impairment

Urgent consultations and escalation

›Mandatory specialist consultations

›Dermatology — urgent evaluation and biopsy support

›Cardiology — for myocarditis concern, ECG, troponin, echocardiography

›Hepatology or gastroenterology — for significant hepatitis

›Nephrology — for interstitial nephritis with rising creatinine

›Pulmonology — for pneumonitis with hypoxemia

›Pharmacy — medication reconciliation and culprit identification

›ICU admission triggers

›Hemodynamic instability

›Respiratory failure

›Fulminant hepatitis or hepatic failure

›Myocarditis with arrhythmia or reduced ejection fraction

02History/hx39

Drug exposure and latency

›Medication timeline

›All medications started in the preceding 2 to 8 weeks including OTC, herbals, supplements

›Latency of 2 to 8 weeks is markedly longer than most other drug eruptions

›Long latency is the leading reason the culprit drug is missed or misattributed

›Faster onset possible with prior sensitization or re-exposure

›High-risk causative drug classes

›Aromatic anticonvulsants — carbamazepine, phenytoin, phenobarbital, lamotrigine

›Allopurinol

›Sulfonamide antibiotics — trimethoprim-sulfamethoxazole, sulfasalazine

›Vancomycin

›Dapsone

›Minocycline

›Prior severe drug reaction or known drug allergy

Symptom timeline and systemic review

›Cutaneous symptom evolution

›Rash onset as a morbilliform eruption

›Progression to oedematous, confluent, infiltrated erythema over days

›Facial oedema — periorbital and perioral predominance

›Pruritus

›Constitutional symptoms

›Fever, often high-grade

›Malaise, fatigue

›Sore throat, lymph node swelling

›Organ-directed review of systems

›Jaundice, dark urine, right upper quadrant pain — hepatitis concern

›Reduced urine output — nephritis concern

›Dyspnea, cough — pneumonitis concern

03Physical Exam/exam32

Skin and lymphatic examination

›Cutaneous findings

›Morbilliform maculopapular eruption

›Becomes oedematous and infiltrated, often confluent

›Facial oedema — a hallmark early finding

›Purpura, pustules, or targetoid lesions may co-occur and do not exclude DRESS

›Skin desquamation in the later phase

›Body surface area involvement often exceeds 50%

›Lymphatic findings

›Lymphadenopathy at two or more sites — cervical, axillary, inguinal

Vital signs and organ system screening

›Vital signs

›Fever, frequently above 38.5°C

›Blunted or absent fever response possible in elderly or immunosuppressed patients — do not exclude DRESS on normothermia alone

›Tachycardia

›Hypotension — consider myocarditis in addition to sepsis or capillary leak

›Hepatic and abdominal examination

›Hepatomegaly

›Right upper quadrant tenderness

›Scleral icterus

›Cardiopulmonary examination

›Tachypnea, crackles — pneumonitis

›New murmur, gallop, jugular venous distension — myocarditis with heart failure

›Muffled heart sounds — pericardial involvement, rare

›Renal-directed examination

›Peripheral oedema

›Reduced urine output on catheter monitoring where placed

04Differential Diagnosis/ddx25

DRESS mimics and SCAR spectrum

›Stevens-Johnson syndrome and toxic epidermal necrolysis

›ICD-10 L51.1 for SJS, L51.2 for TEN

›Nikolsky-positive blistering and mucosal erosions not typical of DRESS

›Shorter latency, typically 1 to 3 weeks after drug start

›Acute generalized exanthematous pustulosis

›SNOMED CT acute generalized exanthematous pustulosis concept

›Numerous small nonfollicular pustules, neutrophilia

›Onset often within 48 hours of the culprit drug, typically an antibiotic

›Rapid resolution within 7 to 10 days after withdrawal

›Morbilliform drug eruption

›ICD-10 L27.0

›No facial oedema, organ involvement, or eosinophilia

›Onset 4 to 14 days after drug start — shorter latency than DRESS

›Serum sickness-like reaction

›Fever, urticarial rash, arthralgia

›No visceral organ involvement pattern of DRESS

Other conditions to exclude

›Infectious mimics

›Viral exanthem — EBV, CMV, HHV-6, measles, acute HIV

›Streptococcal or staphylococcal toxin-mediated illness

›Kawasaki disease in pediatrics

›Hematologic and autoimmune mimics

›Hypereosinophilic syndrome

›Lymphoma with paraneoplastic eosinophilia and rash

›Adult-onset Still disease

›Systemic lupus erythematosus flare

05Laboratory Tests/lt32

RegiSCAR-relevant baseline labs

›Complete blood count with differential

›Eosinophilia — RegiSCAR criterion

›Absolute eosinophil count above 0.7 x10^9/l, or above 10% if leukocyte count is low, per RegiSCAR scoring

›Atypical lymphocytosis — RegiSCAR criterion

›A normal eosinophil count on a single draw does not exclude early DRESS — repeat testing as illness evolves

›Comprehensive metabolic panel

›Creatinine and urea — interstitial nephritis screening

›Electrolytes

›Liver panel

›AST, ALT, ALP, bilirubin

›Hepatitis is the most common visceral involvement and the leading cause of DRESS mortality

›Obtain at presentation and trend serially through hospitalization

›Coagulation studies if severe hepatitis is suspected — synthetic dysfunction risk

Organ-specific and viral workup

›Cardiac workup for myocarditis concern

›Troponin

›Obtain in all suspected or confirmed DRESS, because myocarditis can present late and is a leading cause of death

›BNP or NT-proBNP if heart failure is suspected

›ECG in all suspected DRESS at presentation and with any new cardiopulmonary symptom

›Renal workup

›Urinalysis with microscopy — sterile pyuria or eosinophiluria supports interstitial nephritis

›Pulmonary workup

›Arterial or venous blood gas if hypoxemic

›Herpesvirus reactivation testing

›HHV-6 PCR or serology

›HHV-6 reactivation typically follows 2 to 3 weeks after DRESS onset and correlates with severity and relapse

›HHV-7, CMV, and EBV reactivation may occur in sequence with HHV-6

06Diagnostic Tests/dt33

Scoring Systems

›RegiSCAR scoring system for DRESS

›Fever 38.5°C or above

›Enlarged lymph nodes at two or more sites

›Eosinophilia

›Atypical lymphocytosis

›Skin involvement

›Extent greater than 50% body surface area

›Rash suggestive of DRESS

›Biopsy suggestive of DRESS

›Organ involvement — liver, kidney, lung, heart, pancreas, or other

›Resolution greater than 15 days

›Exclusion of alternative causes — ANA, blood cultures, hepatitis serology, mycoplasma or chlamydia serology

›Score interpretation

›Score below 2 — no case

›Score 2 to 3 — possible case

›Score 4 to 5 — probable case

›Score above 5 — definite case

MRI

›MRI role in DRESS

›Not routinely indicated for diagnosis

›Cardiac MRI for suspected myocarditis when hemodynamically stable

›Late gadolinium enhancement supports the myocarditis diagnosis

›CT use by organ involvement

›CT chest for pneumonitis with hypoxemia not explained by exam alone

›CT abdomen for severe hepatitis complications or to exclude alternative hepatobiliary pathology

›Contrast avoidance considerations if acute kidney injury is present

07Disposition/dispo24

Admission and level-of-care criteria

›Admission indications

›All patients with suspected or confirmed DRESS and any organ involvement

›Inability to ensure reliable cessation of the culprit drug as an outpatient

›ICU-level care criteria

›Fulminant hepatitis or hepatic failure

›Myocarditis with hemodynamic instability or arrhythmia

›Respiratory failure from pneumonitis

›Shock from any organ source

Transfer criteria

›Transfer to a tertiary center indications

›Need for cardiology, hepatology, or critical care expertise not locally available

›Fulminant myocarditis requiring mechanical circulatory support evaluation

›Stabilize before transfer

›IV access secured

›Culprit drug identified and documented

›RegiSCAR score calculated and documented

Discharge criteria and follow-up planning

›Criteria for outpatient management, mild organ-limited disease only

›Stable vitals

›No significant organ involvement on labs and exam

›Reliable follow-up arranged within days

›Follow-up planning

›Dermatology follow-up

›Repeat liver and renal function within 1 to 2 weeks

›Thyroid function testing scheduled at 6 weeks, 3 months, 6 months, and 12 months after recovery

›Late autoimmune thyroiditis is a recognized DRESS sequela and is routinely missed without scheduled surveillance

08Treatment/t64

Culprit drug cessation and avoidance

›Immediate and complete withdrawal of the culprit drug

›Class I recommendation based on expert consensus

›Never rechallenge with the culprit drug

›Cross-reactivity precautions

›Aromatic anticonvulsants — carbamazepine, phenytoin, phenobarbital, lamotrigine — cross-react with one another

›Cross-reactivity reported in a substantial proportion of patients — avoid the entire aromatic anticonvulsant class after a reaction to one member

›Select a non-aromatic anticonvulsant alternative, such as valproate or levetiracetam, if ongoing seizure control is required

›Document the reaction and the cross-reactive class in the allergy record

Symptom management

›Topical therapy

›Topical corticosteroid, medium potency, for cutaneous inflammation

›Limited course 7 to 14 days

›Emollients for skin barrier support

›Antihistamine for pruritus

›Cetirizine 10 mg PO daily

›Hydroxyzine 10 to 25 mg PO q6h PRN pruritus

›Antipyretic and analgesic dosing

›Acetaminophen 650 to 1000 mg PO q6h PRN

›Maximum 3 g per day if hepatitis is present, otherwise standard maximum 4 g per day

›NSAIDs, such as ibuprofen 400 mg PO q6h PRN — avoid if hepatic or renal involvement is present

Systemic corticosteroid therapy

›Moderate to severe DRESS with organ involvement

›Prednisone or prednisolone 0.5 to 1 mg/kg/day PO

›Taper over 8 to 12 weeks or longer, not weeks alone

›Rapid taper is a recognized cause of relapse — the underlying immune and viral-reactivation process outlasts brief steroid courses

›IV methylprednisolone 1 to 2 mg/kg/day for severe or organ-threatening disease

›Pulse-dose methylprednisolone 1000 mg IV daily for 3 days for fulminant myocarditis or hepatic failure, then transition to an oral taper

›Monitoring cadence during corticosteroid therapy

›Glucose monitoring at least every 6 hours during high-dose or pulse therapy

›Blood pressure and electrolytes, particularly potassium, checked daily during pulse dosing

›ECG surveillance for corticosteroid-induced hypokalemia — U waves, QT prolongation, arrhythmia risk

›Therapy-not-working troubleshooting

›Rebound or flare during taper

›Return to the last effective dose and extend the taper interval rather than resuming a rapid schedule

›No improvement after 5 to 7 days of adequate corticosteroid dosing

›Reassess for an unrecognized ongoing culprit exposure or an alternative diagnosis

›Escalate to steroid-sparing therapy

Steroid-sparing and refractory therapy

›IVIG

›2 g/kg total dose divided over 2 to 5 days

›Evidence limited — considered an adjunct in steroid-refractory or steroid-contraindicated cases

›Avoid in IgA deficiency — anaphylaxis risk

›Infusion monitoring

›Begin at a slow initial rate, increase incrementally if tolerated after the first 30 minutes

›Vital signs every 15 to 30 minutes during infusion

›Cyclosporine

›3 to 5 mg/kg/day PO divided BID for steroid-refractory disease

›Monitor renal function and blood pressure — nephrotoxicity risk compounds any DRESS-related nephritis

›Mycophenolate mofetil

›1000 mg PO BID as a steroid-sparing agent in selected refractory or relapsing cases

›Monitor complete blood count for cytopenia

Organ-specific management

›Hepatitis

›Hepatitis is the most common visceral involvement and the most common cause of DRESS-related death

›Serial liver enzymes and coagulation studies

›Avoid additional hepatotoxic drugs, including supratherapeutic acetaminophen

›Hepatology consultation for fulminant hepatic failure — liver transplant evaluation in extreme cases

›Interstitial nephritis

›Serial creatinine and urine output monitoring

›Avoid nephrotoxic drugs, including NSAIDs and nephrotoxic antibiotics, and iodinated contrast where avoidable

›Pneumonitis

›Supplemental oxygen to target saturation

›Corticosteroid therapy as above; escalate respiratory support as needed

›Myocarditis

›Leading cause of death in DRESS and can present late, after cutaneous findings have improved

›Maintain ECG and troponin surveillance even as skin findings resolve

›Cardiology consultation, telemetry, echocardiography

›Fulminant cases may require mechanical circulatory support, including intra-aortic balloon pump or ECMO, as a bridge

09Special Populations/sp26

Pregnancy

›Pregnancy-specific considerations

›DRESS in pregnancy is rare — manage with maternal-fetal medicine involvement

›Systemic therapy modifications

›Prednisone — preferred systemic corticosteroid in pregnancy, relatively safe

›Cyclosporine — Category C; use only if benefit outweighs risk

›IVIG — generally considered safe in pregnancy

›Mycophenolate mofetil — contraindicated in pregnancy, teratogenic

›Culprit anticonvulsants in pregnancy

›Aromatic anticonvulsant avoidance complicated by the need for seizure control — obstetric and neurology co-management required

›Fetal monitoring for maternal systemic illness or hemodynamic instability

Geriatric

›Older adult considerations

›Allopurinol is a leading culprit in elderly patients, particularly with reduced renal clearance

›Allopurinol dose should be renally adjusted at initiation to reduce DRESS risk

›Blunted fever response — normothermia does not exclude DRESS

›Reduced physiologic reserve — higher risk of decompensation with organ involvement

›Polypharmacy complicates culprit identification

›Corticosteroid adverse effects — hyperglycemia, delirium, bone loss — more pronounced; monitor closely during a prolonged taper

Pediatrics

›Pediatric-specific considerations

›Aromatic anticonvulsants remain a leading pediatric culprit

›Weight-based corticosteroid dosing

›Prednisone or prednisolone 0.5 to 1 mg/kg/day PO, same weight-based dosing as adults

›Verify against current pediatric guideline before use

›IVIG 2 g/kg total dose divided over 2 to 5 days

›Verify against current pediatric guideline before use

›Lower threshold for cardiology involvement given the nonspecific presentation of pediatric myocarditis

10Background/b38

Epidemiology

›Incidence and prevalence

›DRESS incidence estimated at approximately 1 in 1,000 to 1 in 10,000 drug exposures

›No clear sex predilection

›Can occur at any age, reported across both pediatric and geriatric populations

›Mortality

›DRESS case fatality reported at approximately 10%

›Hepatitis accounts for the largest share of DRESS-related deaths

›Myocarditis, though less common, carries a disproportionately high mortality when present

›Drug causality

›Aromatic anticonvulsants, allopurinol, and sulfonamides account for a large majority of identified culprits

›Allopurinol-associated DRESS risk rises with a higher starting dose and reduced renal function

Pathophysiology

›Immune mechanism

›Delayed-type, Type IV, hypersensitivity reaction — T-cell mediated

›Drug-specific T-cell activation via HLA presentation, analogous to SJS/TEN but with a distinct cytokine profile favoring eosinophil recruitment and survival

›Eosinophil and cytokine-driven organ inflammation, including IL-5-mediated eosinophil expansion

›Genetic susceptibility

›HLA-B*58:01 — allopurinol-associated DRESS

›HLA-A*31:01 — carbamazepine-associated DRESS

›Herpesvirus reactivation

›Sequential reactivation of HHV-6, followed by HHV-7, CMV, and EBV in a substantial proportion of cases

›Reactivation typically occurs 2 to 3 weeks after DRESS onset

›HHV-6 reactivation is associated with disease severity, relapse, and possibly the late autoimmune sequelae

›Late autoimmune sequelae mechanism

›Autoimmune thyroiditis, Hashimoto or Graves pattern, is the most commonly reported late sequela

›Onset typically weeks to months after acute recovery

›Proposed link to HHV-6 reactivation-driven autoimmune activation

11Patient Discharge Instructions/pdi22

copy discharge instructions

›Medication allergy warning

›The medication that caused this reaction, and its related drug class, has been documented as a severe allergy in your medical record

›Never take this medication or a chemically related medication again

›If your reaction was to an anticonvulsant such as carbamazepine, phenytoin, phenobarbital, or lamotrigine, avoid all of these medications, not only the one you took

›Tell every doctor, dentist, and pharmacist about this allergy at every visit

›Obtain a medical alert bracelet or wallet card listing the specific drug and drug class to avoid

›Symptom and recovery expectations

›Skin symptoms typically improve over 1 to 3 weeks but organ involvement can persist longer

›Fatigue and malaise may continue for weeks after skin findings resolve

›Follow-up monitoring schedule

›Liver and kidney function blood tests within 1 to 2 weeks of discharge

›Thyroid function blood tests at 6 weeks, 3 months, 6 months, and 12 months after recovery

›Thyroid problems, an underactive or overactive thyroid, can develop months after this illness without early symptoms — this scheduled testing is how it is caught

›Dermatology follow-up appointment

›Cardiology follow-up if you had heart involvement during this illness

›Return to emergency department immediately for

›Fever above 38°C (100.4°F)

›New or worsening rash, blistering, or skin peeling

›Yellowing of the skin or eyes, or dark urine

›Reduced urine output

›Chest pain, palpitations, shortness of breath, or fainting

›New swelling of the face or difficulty breathing

12References/r16

Guidelines and key sources

›Cardones AR. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Pathophysiology, Diagnosis, and Management. Dermatologic Clinics. 2020

›Overview of pathogenesis, RegiSCAR criteria, and management approach

›Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the Clinical Pattern of Cutaneous Side-Effects of Drugs with Systemic Symptoms: Does a DRESS Syndrome Really Exist? British Journal of Dermatology. 2007

›Original RegiSCAR scoring system publication

›Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and the Immune System. International Journal of Molecular Sciences. 2017

›Herpesvirus reactivation mechanism and immune pathophysiology

›Chen YC, Chiu HC, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms: A Retrospective Study of 60 Cases. Archives of Dermatology. 2010

›Clinical course, organ involvement patterns, and outcomes

›Husain Z, Reddy BY, Schwartz RA. DRESS Syndrome: Part II. Management and Therapeutics. Journal of the American Academy of Dermatology. 2013

›Corticosteroid taper approach and steroid-sparing therapy review

›Chen YC, Cho YT, Chang CY, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms: A Drug-Induced Hypersensitivity Syndrome with Variable Clinical Features. Dermatologica Sinica. 2013

›Late autoimmune sequelae including thyroiditis

Evidence-based sources

›Reviews and criteria

›RegiSCAR diagnostic criteria and scoring reference

›Shiohara T, Mizukawa Y. Drug-Induced Hypersensitivity Syndrome (DiHS)/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Update in 2019. Allergology International. 2019

›JACI In Practice review on diagnosing and managing DRESS

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.